Skip to main content
. Author manuscript; available in PMC: 2019 Feb 15.
Published in final edited form as: Clin Cancer Res. 2018 Mar 7;24(16):3867–3877. doi: 10.1158/1078-0432.CCR-17-3236

Figure 4.

Figure 4

Training and validation of the miRNA recurrence classifier in the FFPE specimens in clinical cohorts 2 and 3. A and G) Depict MRC risk score violin plots from Cox regression model of the 8-miRNA signature in the training and validation cohorts, respectively. B, C, D and H, I, J) Stage-wise Kaplan Meier plots for the recurrence-free interval in the training (N=165) and validation (N=139) cohorts, stratified based on the MRC risk scores and E and K) Receiver Operating Characteristic (ROC) curves achieved with MRC risk-scores as well as its combination with the tumor stage and lymphatic invasion in the training and validation cohorts, respectively. F and L) Hazard Ratios of the miRNA classifier, NCCN risk classification and other clinicopathological variables presented for stage II CRC from both cohorts.